# OxTium

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxtium

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.oxtium.com
- Latest round: Series A (Jun 10, 2026)
- Investors on record: 3

## About

Based in Shenzhen, China and founded in 2022, Shenzhen Jindu Biomedical Technology Co., Ltd., trading as OxTium, specializes in providing advanced biomedical research solutions. In June 2026, OxTium closed Series A funding led by GTJA Investment Group.

The company works with researchers in the life sciences field and clinical laboratories to offers a suite of products centered around its flagship BioFord™? platform. This platform serves as a one-stop solution for biomedical research, incorporating advanced AI model development, bioinformatics computational services, and AI translational medicine products. It aims to facilitate research for academic institutions, hospitals, and biotechnology companies, providing robust analytical tools for genomic and proteomic data analysis. 

The company’s revenue is generated by service subscriptions and direct partnerships, typically involving customized agreements for access to its platform and associated services. These agreements feature tiered pricing structures based on the extent of services utilized, thus allowing clients to scale according to their research needs. Additionally, proprietary products such as the GeneLLM® multi-omics medical model are offered under various pricing plans to cater to both individual researchers and larger institutions.

## Funding rounds

- Series A, Jun 10, 2026 — GTJA Investment Group
- Angel, Oct 15, 2025 — HSG
- Angel, Nov 30, 2023 — Sangel Capital

## Investors

- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Angel
- HSG (https://capitalatlas.ai/funds/hsg) — Angel
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A